Infection and killing of multiple myeloma by adenoviruses

Area of Science:

• Oncology
• Virology
• Gene Therapy

Background:

• Oncolytic virotherapy utilizes viruses to selectively target and destroy cancer cells.
• Adenovirus serotype 5 (Ad5) is an approved oncolytic virus for solid tumors.
• Multiple myeloma (MM) is a hematologic malignancy with limited treatment options.

Purpose of the Study:

• To evaluate the efficacy of Ad5 and low-seroprevalence adenoviruses as oncolytic agents against multiple myeloma.
• To compare the oncolytic potential of various adenovirus serotypes against MM cells and normal hematopoietic cells.

Main Methods:

• In vitro and in vivo studies using multiple myeloma cell lines and primary patient samples.
• Assessment of viral infection, replication, and cell killing capabilities of different adenovirus serotypes.
• Analysis of viral binding and entry mechanisms into myeloma cells.

Main Results:

• Ad5 productively infects and kills multiple myeloma cell lines both in vitro and in vivo.
• Adenovirus serotypes Ad5, Ad6, Ad26, and Ad48 effectively kill CD138(+) MM cells with minimal toxicity to normal CD138(-) cells.
• While Ad11 and Ad35 exhibit high binding to MM cells, they fail to replicate and induce cell death, unlike Ad5, Ad6, Ad26, and Ad48.

Conclusions:

• Ad5 and certain low-seroprevalence adenoviruses demonstrate significant oncolytic activity against multiple myeloma.
• These adenoviruses show a favorable selectivity profile, targeting cancer cells while sparing normal cells.
• Ad5 and other promising adenovirus serotypes warrant further investigation as potential oncolytic therapies for MM and other hematologic malignancies.